Navigation Links
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Date:9/30/2008

Funding Proceeds to Support R&D Efforts and Clinical Trials Advancing the BiTE Therapeutic Antibody Platform

BETHESDA, Md., Sept. 30 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has entered into a definitive agreement with various institutional investors to raise $40 million in a private placement of its common stock and warrants.

Under the terms of the definitive agreement, Micromet is expected to sell approximately 9.4 million shares of common stock and warrants to purchase approximately 2.8 million shares of common stock at a total purchase price of $4.25 per unit, with each unit consisting of one share of common stock and a warrant to purchase 0.30 shares of common stock. The warrants are exercisable at $4.63 per share and will expire five years after the date of grant. The closing of the transaction, which is expected to occur on or about October 2, 2008, is subject to customary closing conditions. Piper Jaffray & Co. served as sole bookrunning lead placement agent, with RBC Capital Markets acting as co-lead placement agent, and Natixis Bleichroeder serving as financial advisor on the offering.

The net proceeds of the financing will be used for continued research and development of Micromet's product candidates and operational expenses including the advancement of clinical trials for the company's lead BiTE antibody blinatumomab (MT103/MEDI-538).

This news release is not an offer to sell or the solicitation of an offer to buy the securities discussed herein. These securities have not been registered under th
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
2. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
3. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
5. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
6. Micromet to Present at Two Upcoming Investor Conferences
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
9. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
10. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com announces ... available in its catalogue: ,, Neurostimulation ... http://www.reportlinker.com/p0164232/Neurostimulation---A-Global-Market-Perspective.html ,, The world ... base of aging population, and the resultant ...
(Date:12/2/2009)... Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... a dose confirmation and dosimetry trial of Cotara® in ... of brain cancer. Cotara is a targeted monoclonal ... potential new treatment for GBM. Cotara specifically targets ...
(Date:12/2/2009)... Cell announced today,a feasibility study evaluating the preclinical ... product which combines technology from Weill,Cornell Medical College ... to,treat inherited anemias such as Cooley,s Anemia. , ... a series of technologies to expand, ex vivo,populations ...
(Date:12/2/2009)... The world is going through,extraordinary times; markets are in ... It turns out that the pharma industry has been,relatively ... a,vacation. , During the midst ... & Johnson inaugurated an R&D center in Shanghai, the ...
Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... Dmitriy Ovcharenko, Rich Jarvis, , ... , ... experimental tool for reducing the expression of specific , ... function analysis, target , validation, ...
... Trace amounts of ribonuclease (RNase) , ... ubiquitous in the laboratory environment--on your skin, in the , ... bare hands or on anything left , ... or eliminate RNase contamination. However, determining which , ...
... , ... Cenix Pre-designed siRNAs to Human, Mouse, and Rat , ... Silencer Validated siRNAs , ... Superior siRNA Design Combined with High , Quality Custom RNA ...
Other Biology Technology:Delivering siRNAs to Difficult Cell Types 2Delivering siRNAs to Difficult Cell Types 3Delivering siRNAs to Difficult Cell Types 4Delivering siRNAs to Difficult Cell Types 5Delivering siRNAs to Difficult Cell Types 6Delivering siRNAs to Difficult Cell Types 7Combat RNase Contamination in the Lab 2Combat RNase Contamination in the Lab 3Combat RNase Contamination in the Lab 4Combat RNase Contamination in the Lab 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 2IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 3IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 4IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 6IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 7IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 8IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 9IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 10
(Date:12/2/2009)... strengthen the evidence that people who smoke cigarettes over ... for developing colorectal cancer, even after adjusting for other ... not to smoke, or to quit as soon as ... vice president emeritus, epidemiology and surveillance research at the ...
(Date:12/2/2009)... cigarette smoking scenes in movies are more likely ... may be part of the acculturation process associated ... , "Our study supports an R-rating for smoking ... implementation of the World Health Organization Framework Convention ...
(Date:12/2/2009)... Smoky Mountain forest,s woodland herb population has shown that ... recover from logging, according to Purdue University research. , ... 80 years ago, the distribution of trillium plants on ... undisturbed areas. Michael Jenkins, a Purdue assistant professor of ...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Study finds logging effects vary based on a forest's history, climate 2University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 1University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 2University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 3University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 4University of Florida Shands Cancer Center Selects OnCore 28r 29 to Support its Collaborative Research Goals 13034 5MultiNational Underwriters Is Now HCC Medical Insurance Services 51740 1MultiNational Underwriters Is Now HCC Medical Insurance Services 51740 2 26quot 3BThe Safe 26quot 3B Way To Protect Against The Anguish Of Disaster Recovery 51736 1 26quot 3BThe Safe 26quot 3B Way To Protect Against The Anguish Of Disaster Recovery 51736 2 26quot 3BThe Safe 26quot 3B Way To Protect Against The Anguish Of Disaster Recovery 51736 3
... NY, November 18, 2008 -- Researchers at the University of ... have been used to block and reverse type 1 diabetes ... of the National Academy of Sciences , was led by ... and an expert in the field of autoimmunity. , "The ...
... LAFAYETTE, Ind. - Materials engineers have created a new ... if perfected, might be used for environmental cleanup, water ... last longer than conventional filters for separating oil from ... traits that are usually mutually exclusive. Researchers attached the ...
... German Research Foundation) is intensifying the international ... meeting in Bonn the Grants Committee responsible ... of 13 additional Research Training Groups, 7 ... These enable doctoral researchers to cooperate closely ...
Other Biology News:New filtering technology has environmental, industrial applications 2New filtering technology has environmental, industrial applications 3National and international doctoral training 2National and international doctoral training 3National and international doctoral training 4National and international doctoral training 5National and international doctoral training 6National and international doctoral training 7
One unit is equal to 10Kb (insert DNA + vector). The final cost will increase or decrease according to the final assembled genome size. The price does not include genome annotation....
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Biology Products: